Lyell Immunopharma, Inc. (LYEL) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Lyell Immunopharma, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -1.92x | -0.49x | -2.08x | -4.68x | -7.51x | -20.37x |
| P/B Ratio | 2.12x | 0.44x | 0.74x | 1.03x | 2.02x | 5.80x |
| P/S Ratio | 14614.51x | 2743.40x | 3745.44x | 10.12x | 176.41x | 536.97x |
| Profitability | ||||||
| Gross Margin | -31952.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -566038.9% | -588123.0% | -190006.2% | -220.9% | -2016.7% | -2732.6% |
| Net Margin | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% | -2636.3% |
| EBITDA Margin | -533986.1% | -328923.0% | -174429.2% | -199.6% | -1888.8% | -2777.6% |
| Liquidity | ||||||
| Current Ratio | 5.28x | 7.06x | 16.07x | 17.59x | 13.40x | 12.53x |
| Quick Ratio | 5.28x | 7.06x | 16.07x | 17.59x | 13.40x | 12.53x |
| Leverage | ||||||
| Debt/Equity | 0.17x | 0.15x | 0.10x | 0.08x | 0.07x | 0.08x |
YoY = year-over-year change. Source: FMP..